cyrilzakka/clinical-trials huggingface dataset:
Discovery of Biological Signatures for Cruciferous Vegetable Intake (single Serving)

The purpose of this project is to study the molecular and metabolic profiles in human plasma, urine and microbiome composition following the consumption of broccoli sprouts.

The investigators wish to examine metabolic and molecular markers found in blood and in urine after a single dose of sprouts, and evaluate the importance of the gut microbiome on these parameters. Some subjects will receive broccoli sprouts that are grown in deuterium oxide, a commonly used non-toxic, non-radioactive label for vegetables (Tang, Qin et al. 2005), so researchers can identify metabolites in blood and urine that are directly from consumed sprouts. The investigators plan to feed subjects a standardized breakfast and either broccoli sprouts or alfalfa sprouts (control) and look at the presence of metabolites and activity in the blood and urine 3, 6, 24, 48 and 72 hours following intake as well as changes in microbiome composition.

Eligibility Criteria:
Inclusion Criteria:

* Healthy men and women, 18-60 years of age
* Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during the study
* Willing to stop cruciferous vegetable and probiotic supplement, food and beverage intake 1 week prior to and during the study
* Willing to complete a 10-day food diary during the study
* Must be able to give written informed consent

Exclusion Criteria:

* Body Mass Index (BMI) \<18.5 or \>30.0 kg/m2
* Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months
* Pregnancy, breastfeeding, or planning to become pregnant before completing the study
* Engaging in vigorous exercise more than 7 hours per week
* Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years.
* Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat)
* Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis)
* Use of oral antibiotic medication within the 6 months
Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion

Dental erosions, the chemical dissolution of enamel without bacterial involvement, are considered to be an established complication of gastroesophageal reflux disease (GERD) by the Montreal global consensus statement. Given the high prevalence of dental erosions and the absence of any pH-impedance data or medical management guidelines for GERD-associated dental erosions, reflux characteristics will be characterized using questionnaires, endoscopy and esophageal pH-impedance testing, in successive patients dental erosions referred by dentists for evaluation of GERD. For assessment of the role of additional factors besides H+ activity in the refluxate, a sample of gastric juice will be aspirated during endoscopy and frozen for analysis of pepsin and other proteases. Prognostic factors for progression of dental erosions will be determined by repeating the evaluation after chronic dosing with esomeprazole 20mg twice-daily, which is prescribed to all patients.


Eligibility Criteria:
Inclusion criteria:

* Successive male and female patients
* Over 18 years of age presenting to the University of Bern Department of Dentistry and affiliated dentists
* Dental erosions

Exclusion criteria:

* Non-reflux causes of erosion
* Reduced salivary flow and buffering capacity
* History of bruxism, eating disorders, recurrent vomiting, severe obesity (BMI\>35kg/m2) or past bariatric surgery
* Dietary or abrasive causes for dental erosion
Mechanisms Behind Microvascular Dysfunction in INOCA

The purpose of the study is to identify the causes of chest pain in patients experiencing chest pain with no signs of narrowing in the coronary arteries of the heart.

A significant number of patients with ischemic heart disease do not exhibit coronary obstruction, leading to their symptoms being attributed to coronary microvascular dysfunction, a condition known as ischemia with no obstructive coronary artery disease (INOCA). Despite a considerable patient population affected by INOCA, the specific mechanisms underlying this microvascular dysfunction are not fully understood, often resulting in a lack of targeted treatment. There is evidence to suggest that exercise capacity is linked to coronary microvascular function, an area yet to be explored.

This study aims to identify mechanisms underlying Coronary microvascular dysfunction (CMD) in angina and to assess whether exercise training can improve the condition. In study part I 30 patients with impaired coronary microvascular function and 30 asymptomatic controls will be studied to identify vascular and related molecular mechanisms underlying INOCA by investigating microvascular function in the heart and in cutaneous tissue, skeletal muscle, and adipose tissue.

Eligibility Criteria:
Inclusion Criteria:

Only for angina patients: Have CMD, defined as myocardial bloodflow re-serve (MBFR) \< 2.5 or hyperemic myocardial blood flow (hMBF) \< 2.3ml/g/min

Exclusion Criteria:

* Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile
* Heart failure, defined as left ventricular ejection fraction of less than 40%
* Uncontrolled hypertension defined as blood pressure above target 140/90 for all
* Co-morbidity resulting in \<1 year expected survival
* Considered by the investigator, for any reason, to be an unsuitable candidate for the study.
* Unable or unwilling to exercise, e.g. due to arthritis or injury\*
* Already are regularly physically active and/or have a maximal oxygen uptake \>45 ml/kg/min
* The subject has a known allergy to either: norepinephrine, adenosine, ketorolac, and or ascorbic acid (vitamin C).
Comparison of Current Subgingival Debridement Methods

Our study aimed to compare the effectiveness of current subgingival debridement methods used in the treatment of Stage 1 and Stage 2 periodontitis patients, the aesthetic condition achieved after these treatments, and the pain felt during treatment.

90 female patients who were diagnosed with chronic periodontitis (Stage 1-2) and required supra-subgingival scaling for treatment purposes, and who volunteered to participate in the study, were included in the study. Three treatment groups were determined. 30 people were included in each group. Periodontal examination was performed before and after the treatments in the 1st month, 3rd month and 6th month and the data on the collected periodontal parameters were analyzed.

Periodontal parametreler Gingival index, plaque index, periodontal pocket depth and bleeding index on probing.

It was evaluated with the visual analog scale for pain and aesthetics.

Eligibility Criteria:
Inclusion Criteria:

* Systemically healthy patient (without known chronic disease)
* Periodontal diagnostic data (Gingival Index, Plaque Index, Periodontal pocket depths, Attachment loss, Radiological data-Bone loss data) are complete
* Treatments diagnosed with stage 1-2 periodontitis and those who have not had periodontal treatment in the last 6 months

Exclusion Criteria:

* Having a systemic disease
* Pregnant and lactating women
* smoker
* Those who do not want to participate in the study
Interprofessional Group Intervention to Promote Faculty Wellbeing and Engagement

A randomized trial of an interprofessional intervention to reduce burnout and enhance professional engagement in physicians, certified nurse midwives, and nurse practitioners.

To test the hypothesis that an intervention involving self-facilitated interprofessional group meetings would result in improvement in wellbeing and to determine whether use of a written curriculum provided increased benefit, the following study is conducted:

Practicing clinical faculty in the Department of Obstetrics and Gynecology at the Massachusetts General Hospital were recruited to participate in three monthly small groups over dinner. Participants were randomized to a control group, which met without any specified guidelines for discussion content, or to receive an intervention which consisted of a one-page discussion guide addressing themes relevant to challenges in the healthcare environment: reframing challenging patient interactions; embracing uncertainty in work; and coping with errors, near misses, and bad outcomes. Outcomes included burnout, empowerment and engagement in work, stress from uncertainty assessed using validated metrics, and perception of of collegiality and community.

All participants were also offered the option of participating in evaluation of biomarkers. To test the hypothesis that an increased sense of bonding and relational connection, and reduced stress levels would be reflected by changes in hormone levels during the meeting and over the course of the study. Faculty who opted into this portion of the study gave the following samples:

Urine Oxytocin before and after the first and third group meetings Salivary Oxytocin before and after the first and third group meetings Salivary Cortisol before and after the first and third group meetings Hair Cortisol at the beginning of the study and at the end of the study (a roughly three month interval).

An optional focus group was conducted after the three monthly sessions.

All participants signed a consent form prior to participating in the study.

Eligibility Criteria:
Inclusion Criteria:

* Physican in the Department of Obstetrics and Gynecology at Massachusetts General Hospital
* Nurse Practitioner in the Department of Obstetrics and Gynecology at Massachusetts General Hospital
* Certified Nurse Midwife in the Department of Obstetrics and Gynecology at Massachusetts General Hospital

Exclusion Criteria:

* None
Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

Neurotensin (NT), a gut hormone and neuropeptide, and GLP-1, as well a gut hormone, increases in circulation after bariatric surgery in rodents and humans and inhibit food intake in mice.

Studies in rodents have shown that a GLP-1 receptor agonist and long acting neurotensin inhibit food intake.

This study investigates whether the synergistic anorexic effects of neurotensin and GLP-1 agonism suggested by animal studies can be translated.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Above 18 years of age
* Normal hemoglobin concentration
* 28\<BMI\<40 kg/m2

Exclusion Criteria:

* Diabetes mellitus
* Truncal vagotomy
* Resection of intestine (apart from appendectomy)
* Tobaccos use
* Nephropathy (serum-creatinin\>130 micromolar or/and albuminuria)
* Liver disease (Alanine transaminase or/and aspartate transaminase\>2 times normal range.)
* Treatment with medication that cannot be paused in 12 hours
* Allergy towards latex or plastic
* Bleeding disorder
Educ'Avk: Recommendations for the Antivitamin K's Gestion

The objective of the project "Educ'Avk", is to document the efficacy of a strategy combining a specific follow up-notebook and education of attending patient with a pedagogic support, comparatively to an usual education on the impact of clinical events at three months (minor or major hemorrhagic events + recurrence of thrombi-embolic's disease).

Standard strategies for the implementation of recommendations are exclusively focused on practitioners. But often they do not appear to be effective (insufficient time accorded per patient, lack of training...).

However some qualitative surveys have shown the benefit of a greater role on the part patient in the process of transmitting recommendations through the practitioner.

In this study, patient education is begun by the angiologist or a pharmacy student under the responsibility of the hospital investigator. Follow-up is realized by the patient's general practitioner.

More patient involvement in the realization of the recommendations could increase the proportion of practitioners who follow the recommendations and decrease the iatrogenicity of antivitamin K (AVK).

Eligibility Criteria:
Inclusion Criteria:

* Able to receive benefit sanitary educational act
* Able to be followed up during three months
* Acute episode of a venous's thrombi embolic illness (venous's thrombosis distal or proximal deep and/or lung embolism)
* A.V.K. treatment for a period of at least three months
* Return to residence (included return to retreat residence no medicalize)
* Informed consent form signed

Exclusion Criteria:

* Distal venous thrombosis limited muscular vein without lung embolism
* Contra-indication of to an A.V.K. treatment
* Difficult comprehension of the french language
* Trouble of visual acuity
* Trouble of superior function incompatible with an educational's act sanitary
* Psycho-social instability incompatible with a regular follow-up of three months (without fixed residence, addictive lapsed)
* Impossibility to return to residence (the return in retreat residence no medicalize is considered as a return to residence)
* Psychiatric pathology not compensated
* Life expectancy less than three months
* Refusal of participation in the study
* Participation in another clinical study
* Anterior inclusion in the study
A Comparison of Different Concentration Ropivacaine for Patient-controlled Epidural Analgesia

To compare the postoperative analgesic effect and the intensity of motor block in different concentration ropivacaine plus fentanyl when used epidurally with a patient-controlled analgesia device after Cesarean delivery.

1. Written informed consent must be obtained before any study specific procedures are undertaken.
2. All patients were received epidural anesthesia with 2% Lidocaine and patient-controlled epidural analgesia (PCEA) for post- operative pain control. PCEA randomly allocated into three groups. Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl, Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl, and Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl. Dermographic data, dosage of PCEA during first 48 hours post-operation，NRS scores, patient satisfaction and the intensity of motor block will be recorded and analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Female undergoing elective Cesarean delivery and receive patient-controlled epidural analgesia

Exclusion Criteria:

* With the comorbidity of chronic heart, lung, liver and renal disease, chronic alcoholism, allergy to ropivacaine, poor epidural function and combine other anesthesia method
Care China-Diabetes

This multicenter, prospective, observational registry will assess efficacy and safety outcomes associated with percutaneous coronary intervention (PCI) with implantation of the CYPHER Select™+ Sirolimus-eluting Coronary Stents in Chinese diabetic patients with coronary artery disease in routine clinical practice.

The study objective is to assess the incidences of major adverse cardiovascular events (MACE; defined as a composite of clinically driven target-lesion revascularization, cardiac death, any myocardial infarction, and stent thrombosis) at 12-month follow-up, and of stent thrombosis at 1-day, and 1- and 12-month follow-up. Pre-specified analyses will be performed among patient subpopulations according to level of glycemic control (HbA1c level \< 6.5% or \> 6.5%); reference vessel diameter by quantitative coronary angiography (\< 2.5 mm and \> 2.5 mm); and stented length (8-18 mm; 23-33 mm; and \>33 mm). Quantitative coronary angiographic (QCA) analysis will be performed at the core lab of the China Cardiovascular Research Foundation for all pre- and post-index procedure angiograms and during the 12-month follow-up period for the pre- and post-reintervention procedures in those cases of clinically-driven PCI revascularization. Also, multivariable analyses will be conducted to investigate potential predictors of 12-month MACE rate in routine clinical practice.

The registry will be conducted at about 45 centers in China, where the CYPHER Select™+ Sirolimus-eluting Coronary Stent is commercially available. Data will be collected on 2,500 diabetic patients treated with the CYPHER Select™ + Sirolimus-eluting Coronary Stent only.

Primary outcome: MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months Secondary outcome: ARC (probable + definite) ST at 1-day, and 1 and 12 months

Eligibility Criteria:
Inclusion Criteria:

* Patients between the ages of 18 and 80 (inclusive) receiving CYPHER SELECT™+ Sirolimus-eluting Coronary Stent according to standard clinical practice when financially feasible
* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
* Patient has diagnosis of diabetes or is diagnosed with it before or during the index procedure hospitalization based on disease diagnosis criteria

Exclusion Criteria:

* Any contraindication to any of the following medications: aspirin, heparin, thienopyridines (clopidogrel/ticlopidine), stainless steel, contrast agents, or sirolimus
* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment
* Cardiogenic shock
* Terminal illness with life expectancy \<1 year
* ST-segment elevation myocardial infarction within 7 days prior to the index procedure
* Any patient who received coronary stent(s) within 1 year
Hepatocellular Carcinoma Imaging Using PSMA PET/CT

The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).

A total of 30 patients will be recruited in this prospective pilot study who have HCC on imaging criteria (LI-RADS 5) for surgical resection, or patients with indeterminate liver lesions (LI-RADS 3 or 4) planned for liver biopsy. 18F-DCFPYL PSMA PET/CT will be performed prior to the planned surgery or liver biopsy

Eligibility Criteria:
Inclusion Criteria:

* Male or female aged 18 years or older at screening
* Has provided written informed consent for participation in the study
* Must have risk factors for HCC e.g. cirrhosis, chronic hepatitis B infection with or without cirrhosis
* Patients with liver lesions ≥1 cm suspicious for HCC but with indeterminate features on CT and MRI meeting LI-RADS 3 or 4 criteria planned for biopsy, OR patients with liver lesions diagnostic of HCC based on CT or MRI meeting LI-RADS 5 criteria planned for surgical resection
* Patients must be willing and able to comply with the protocol and procedures for the duration of the study
* Patients must be available for follow-up

Exclusion Criteria:

* Abdominal surgery or radiotherapy to the abdomen within \<4 weeks of registration. Patients must have recovered from any effects of any major surgery
* Uncontrolled intercurrent illness that is likely to impede participation and or compliance
* Any history of prostate cancer or elevated PSA level for male patients
* Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ
* Participation in another clinical study with an investigational product or another systemic cancer therapy administered in the last 4 weeks
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the study
* Women who are pregnant or lactating
* Cirrhosis due to congenital hepatic fibrosis, vascular disorders (e.g. Budd-Chiari syndrome) or cardiac cirrhosis
Functional Connectivity & Stimulation-enhanced Therapy Post Stroke

After stroke, it is common for individuals to experience hand impairment. This deficit can severely restrict functional ability and independence. Recovery of hand function following stroke is highly variable. In this study, the investigators will use brain imaging to predict individual response to treatment. Survivors of stroke will receive upper extremity therapy while they concurrently receive imperceptible vibration to the wrist aimed to enhance therapy outcomes.

The ability to predict individuals' responses to treatment can enable effective allocation of a treatment to likely responders. The long-term goal is to determine whether acute changes in brain functional connectivity immediately after one treatment session can predict ultimate gains in motor function after completing multiple treatment sessions. The objective of this study is to determine feasibility and to examine association between change in brain functional connectivity after one session and motor gains after completion of all treatment sessions. This study is a prospective single-cohort longitudinal study. The treatment is task-practice therapy (3d/wk, 18-session) accompanied with concurrent imperceptible wrist vibration that is intended to prime the cortical sensorimotor network and enhance hand functional recovery in chronic stroke survivors. Hand function will be assessed before/after therapy and at 1-month follow-up. Connectivity will be assessed using fMRI and EEG before and after a treatment session.

Eligibility Criteria:
Inclusion Criteria:

* Age = 18 or older
* At least 6 months post-stroke
* Moderate upper limb impairment with the ability to participate in hand task practices
* Fingertip touch sensory deficits (e.g., Monofilament\>2.83, 2-point discrimination\>5mm, sense of numbness, tingling)

Exclusion Criteria:

* Complete upper limb deafferentation
* Rigidity (Modified Ashworth Scale=5)
* Botulinum toxin injection within 3 months prior to enrollment or during enrollment
* Brainstem stroke
* Comorbidity (peripheral neuropathy, orthopaedic conditions in the hand that limit ranges of motion, premorbid neurologic conditions, compromised skin integrity of the hand/wrist due to long-term use of blood thinners)
* Concurrent upper extremity rehabilitation therapy
* Language barrier or cognitive impairment that precludes following instructions or providing consent
* MRI incompatible.